

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) An oligonucleotide ~~8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human vitamin D nuclear receptor (SEQ ID NO:3), wherein said oligonucleotide~~ which specifically hybridizes with within nucleotides 1710 to 1757 of a said nucleic acid molecule encoding human vitamin D nuclear receptor (SEQ ID NO:3) and inhibits the expression of human vitamin D nuclear receptor, ~~and wherein the oligonucleotide is a chimeric oligonucleotide.~~
2. (previously presented) The oligonucleotide of claim 1 which is an antisense oligonucleotide.
3. (cancelled)
4. (previously presented) The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (previously presented) The oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (previously presented) The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (previously presented) The oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (previously presented) The oligonucleotide of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (previously presented) The oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. cancelled.
11. (currently amended) The oligonucleotide of claim 1 ~~An oligonucleotide 8 to 50 nucleobases in length which specifically hybridizes with at least an 8 nucleobase portion~~

~~of an active site on a nucleic acid molecule encoding vitamin D nuclear receptor, and wherein~~
the oligonucleotide is a chimeric oligonucleotide.

12. (currently amended) A composition ~~An oligonucleotide~~ comprising the oligonucleotide ~~the compound~~ of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (currently amended) The composition ~~oligonucleotide~~ of claim 12 further comprising a colloidal dispersion system.

14. (currently amended) The composition ~~oligonucleotide~~ of claim 12 wherein the oligonucleotide ~~the compound~~ is an antisense oligonucleotide.

15. (currently amended) A method of inhibiting the expression of vitamin D nuclear receptor in cells or tissues comprising contacting said cells or tissues *in vitro* with the oligonucleotide of claim 1 so that expression of vitamin D nuclear receptor is inhibited.

Claims 16-29 (cancelled).

30. (new) The oligonucleotide of claim 1 wherein said compound comprises a sequence of SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, or SEQ ID NO: 56.